Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

Not read toomuch about the swedish company before but i think this patent covers uses of the 5t4 antigen:

TroVax Notice of Allowance

RNS Number:4606U
Oxford Biomedica PLC
22 November 2005


Immediate Release 22 November 2005

OXFORD BIOMEDICA RECEIVES NOTICE OF PATENT ALLOWANCE EXTENDING TROVAX(R)
PROTECTION IN THE UNITED STATES

Oxford, UK: 22 November 2005 - Oxford BioMedica (LSE: OXB), a gene therapy
company, announced today that the US Patent and Trademark Office has issued a
Notice of Allowance for a key patent application (USSN 09/533,798), which
significantly extends the protection of TroVax, the Company's lead cancer
vaccine. It is expected that the patent will be issued during 2006. This patent
is one of several granted and pending patents that protect the Company's use of
the 5T4 tumour antigen. The Notice of Allowance covers immunotherapy approaches
directed against the 5T4 tumour antigen.

5T4 is a tumour associated antigen that is expressed at high levels on a wide
range of tumour types, including colorectal cancer, renal cell carcinoma and
breast cancer, amongst others. 5T4 expression is frequently correlated with poor
prognosis and metastatic spread. Although present on tumour cells, 5T4 is not
found on any essential organs. These and other unique characteristics make 5T4
an ideal target for immunotherapy treatment in a wide range of cancer types.

Commenting on the Notice of Allowance news, Peter Nolan, Oxford BioMedica's
Senior Vice President for Commercial Development said:
"We are delighted to have been allowed such broad claims for this key US patent.
This Notice of Allowance, together with several other granted and pending
patents, provide clear protection in most major territories for our lead
product, TroVax, as well as next generation cancer vaccines based on the 5T4
antigen. Today's news further strengthens our negotiating position with
potential partners for TroVax as we progress into Phase III development."